Related Experiment Video
Updated: May 28, 2026
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration
Jie Wang1, Zongjie Wang1,2
1Chan Zuckerberg Biohub Chicago, Chicago, IL 60642, USA.
Abstract:
Translating preclinical findings into effective clinical cancer immunotherapies remains a major challenge, mainly because conventional in vitro and animal models often fail to capture the complexity, dynamics, and species-specific features of human immune responses. Organ-on-a-chip (OoC) technologies that combine engineered tissue architectures with precisely controlled microfluidic transport provide human-relevant microphysiological platforms for mechanistic studies of immune-tumor interactions and evaluation of therapeutic efficacy and immunotoxicity under defined microenvironmental conditions. However, immune responses involve time-dependent and interconnected processes, including immune cell trafficking, cytokine programs, metabolic shifts, and cytolysis, that are not adequately resolved by static or endpoint assays. Engineering immune-competent OoC systems therefore requires coordinated design of platform architectures, immune cell incorporation strategies, and integrated measurement workflows capable of capturing dynamic and state-dependent responses. In this review, we summarize engineering strategies for building immune-competent OoC platforms for cancer immunotherapy, focusing on platform architectures, immune cell incorporation methods, and fit-for-purpose assay workflows. Emphasis is placed on embedded sensing modalities (e.g., cytokine, oxygen, and impedance readouts) that provide valuable kinetic and state-variable data. Finally, we discuss key translational challenges, including reproducibility, standardization, and benchmarking, and outline near-term priorities to accelerate the adoption of immune-competent OoC systems in immunotherapy research and development.
Insights
Organ-on-a-chip (OoC) systems offer human-relevant models for cancer immunotherapy research. These advanced platforms capture dynamic immune responses, overcoming limitations of traditional methods for better drug development.
Area of Science:
- Biotechnology and Biomedical Engineering
- Cancer Immunology
- Translational Medicine
Background:
- Preclinical models often fail to accurately predict human immune responses in cancer immunotherapy.
- Existing models lack the complexity and dynamic nature of human immune-tumor interactions.
- Need for human-relevant platforms to study immune cell trafficking, cytokine dynamics, and metabolic shifts.
Purpose of the Study:
- To review engineering strategies for developing immune-competent organ-on-a-chip (OoC) platforms for cancer immunotherapy.
- To highlight the importance of integrated measurement workflows and embedded sensing for dynamic response capture.
- To discuss challenges and future directions for OoC systems in immunotherapy research and development.
Main Methods:
- Summarizing engineering approaches for OoC platform architectures and immune cell incorporation.
- Focusing on integrated assay workflows designed to capture dynamic and state-dependent immune responses.
- Emphasizing the use of embedded sensing modalities (cytokine, oxygen, impedance) for kinetic data acquisition.
Main Results:
- Immune-competent OoC platforms can recapitulate complex, dynamic human immune responses relevant to cancer.
- Embedded sensing provides crucial kinetic and state-variable data for mechanistic studies and therapeutic evaluation.
- OoC systems enable evaluation of therapeutic efficacy and immunotoxicity under controlled microenvironmental conditions.
Conclusions:
- Immune-competent OoC technologies are crucial for advancing cancer immunotherapy by providing human-relevant data.
- Coordinated design of platforms, cell incorporation, and assay workflows is essential for capturing immune dynamics.
- Addressing challenges in standardization and reproducibility will accelerate the adoption of OoC systems in drug development.
